Sugi Predict

Sugi Predict / Compounds / SCHEMBL444202

SCHEMBL444202

SCHEMBL444202

CCOC(=O)C1CCCCN1C(=O)OC(C)(C)C

nearest known ligand 0.64

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ FKBP1A P62942 9/20 0.64
▸ MEN1 O00255 3/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ HSD17B10 Q99714 2/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ GLA P06280 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15893182 1.00 FKBP1A (0.64) FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL24358344 1.00 FKBP1A (0.64) FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL8223617 0.96 FKBP1A (0.58) FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL1401256 0.96 FKBP1A (0.58) FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL440340 0.96 FKBP1A (0.58) FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL23484492 0.89 FKBP1A (0.50) FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL24661351 0.88 FKBP1A (0.65) FKBP1AMEN1KMT2AKDM4EALDH1A1
SCHEMBL2760258 0.87 FKBP1A (0.55) FKBP1AHSD17B10
SCHEMBL927348 0.86 HSD17B10 (0.56) FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL28153746 0.86 HSD17B10 (0.56) FKBP1AMEN1KMT2AHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 — — US claimed
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 — — US disclosed
CN-113993850-B Modulators of integrated stress response pathways 埃沃特克国际有限责任公司 2024-03-29 — — CN disclosed
CN-117098753-A Modulators of integrated stress response pathways 埃沃特克国际有限责任公司 2023-11-21 — — CN disclosed
CN-116964047-A Modulators of integrated stress response pathways 埃沃特克国际有限责任公司 2023-10-27 — — CN disclosed
CN-116761803-A Modulators of integrated stress response pathways 埃沃特克国际有限责任公司 2023-09-15 — — CN disclosed
CN-113993850-A Modulators of integrated stress response pathways 埃沃特克国际有限责任公司 2022-01-28 — — CN disclosed
US-20170210749-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2017-07-27 — — US disclosed
US-9662327-B2 Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer AGIOS PHARMACEUTICALS, INC (US) 2017-05-30 — — US disclosed
CN-105555787-A Process for preparation of diazabicyclooctane derivatives and intermediates therefor MEIJI SEIKA PHARMA CO LT 2016-05-04 — — CN disclosed
US-7595401-B2 Therapeutic compounds and their use in cancer MYRIAD PHARMACEUTICALS, INC. (US) 2009-09-29 — — US disclosed
CN-101490052-A Therapeutic compounds and their use in cancer MYRIAD GENETICS INC (US) 2009-07-22 — — CN disclosed
EP-2038041-A2 THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER Myriad Genetics, Inc. (US) 2009-03-25 — — EP disclosed
EP-2010506-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-Roche AG (CH) 2009-01-07 — — EP disclosed
US-20080146607-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof ROCHE PALO ALTO LLC 2008-06-19 — — US disclosed
US-20070299258-A1 THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER MYRIAD GENETICS, INCORPORATED (US) 2007-12-27 — — US disclosed
WO-2007134298-A2 THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER MYRIAD GENETICS, INC. (US) 2007-11-22 — — WO disclosed
WO-2007122103-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-01 — — WO disclosed
US-20070249589-A1 Novel diazepan derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-10-25 — — US disclosed
WO-2006052962-A2 BICYCLIC TRIAZOLE A4 INTEGRIN INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299258-A1 THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER MCL1, TP53, TUBB3 FKBP1A 926/4885MEN1 1604/4885KMT2A 3222/4885
US-20080146607-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof CNKSR1, RB1, AR FKBP1A 2521/4885MEN1 1757/4885KMT2A 1195/4885
US-20070249589-A1 Novel diazepan derivatives CCR3, CCR1, CCR10 FKBP1A 3689/4885MEN1 2072/4885KMT2A 2954/4885
US-20170210749-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE RNASE1, GZMB, ANXA2 FKBP1A 3303/4885MEN1 1225/4885KMT2A 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.